Skip to content

Observation on the effect of repeated infusion of sub-anaesthetic dose of esketamine on refractory late life depression

Observation on the effect of repeated infusion of sub-anaesthetic dose of esketamine on refractory late life depression

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000036075
Enrollment
Unknown
Registered
2020-08-21
Start date
2020-08-18
Completion date
Unknown
Last updated
2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Late life depression

Interventions

Experimental group:antidepressant+eaketamin
control group:antidepressant+saline

Sponsors

The Affiliated Brain Hospital of Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged >=60 years old, right-handed; 2. In line with the DSM-IV "major depressive disorder" diagnostic criteria, a sufficient course of treatment with at least two antidepressants in the past. A sufficient amount refers to the minimum effective dose, and a full course of treatment refers to the treatment of each of the above drugs for more than 4 weeks , Chronic depression needs to be treated for more than 8 weeks, and the depressive symptoms have not been significantly relieved (the reduction rate of the Hamilton Depression Scale is less than 30%) or the ATHF rating >=3; 3. The current HAMD-17 item >=17 points; 4. Agree to comply with the drug treatment plan required by this project during the research period; 5. The concomitant diseases before the baseline must remain clinically stable; 6. Educational level of elementary school and above, cooperate to complete the project test; 7. The subject or legal guardian agrees to participate in this study and signs an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Meet any other diagnostic criteria of DSM-IV axis I; 2. Hypothyroidism, vitamin B12 or folic acid deficiency, syphilis infection, stroke; 3. History of dementia, brain organic diseases, brain trauma or surgery; 4. Suffering from major physical diseases such as heart, liver, and kidney, cannot tolerate this study; 5. There were clear hallucinations and delusions before entering the group; 6. Have a history of substance or alcohol abuse; 7. Past history of ketamine allergy; 8. Received MECT, TMS treatment within three months; 9. Previous history of epileptic seizures; 10. Patients with angle-closure glaucoma.

Design outcomes

Primary

MeasureTime frame
Hamilton Depression Rating Scale;

Secondary

MeasureTime frame
Mini-Mental State Examination;Magnetic Resonance Imaging;

Countries

China

Contacts

Public ContactYuping Ning

The Affiliated Brain Hospital of Guangzhou Medical University

ningjeny@126.com+86 20 81268720

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026